Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary hypertension in systemic sclerosis.

Christopher P Denton1, Carol M Black

  • 1Center for Rheumatology, Royal Free Hospital, Pond Street, London NW3 2QG, UK. c.denton@rfc.ucl.ac.uk

Rheumatic Diseases Clinics of North America
|July 5, 2003
PubMed
Summary

Systemic sclerosis (SSc) patients have a high risk of developing pulmonary arterial hypertension (PAH). Early screening and treatments like bosentan improve outcomes, but further advances are needed for presymptomatic cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician-patient communication in the treatment of systemic sclerosis-associated interstitial lung disease: A narrative review and recommendations.

Journal of scleroderma and related disorders·2025
Same author

Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis.

ACR open rheumatology·2025
Same author

Guidance for stem cell therapy for juvenile systemic sclerosis patients.

Expert review of clinical immunology·2025
Same author

Publisher Correction: An international perspective on the future of systemic sclerosis research.

Nature reviews. Rheumatology·2025
Same author

An international perspective on the future of systemic sclerosis research.

Nature reviews. Rheumatology·2025
Same author

Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study.

Seminars in arthritis and rheumatism·2025

Area of Science:

  • Cardiology
  • Rheumatology
  • Pulmonology

Background:

  • Pulmonary arterial hypertension (PAH) affects up to 15% of patients with systemic sclerosis (SSc).
  • PAH in SSc carries a high mortality rate and can be isolated or secondary to pulmonary fibrosis.
  • Significant advancements have been made in the assessment and therapy of PAH in SSc.

Purpose of the Study:

  • To review current screening, diagnostic, and therapeutic strategies for pulmonary arterial hypertension in systemic sclerosis.
  • To highlight the importance of early detection and management to reduce SSc-related mortality.

Main Methods:

  • Regular screening using Doppler-echocardiography and pulmonary function tests.
  • Right heart catheterization for diagnostic and prognostic information.

Related Experiment Videos

  • Review of current treatment options including anticoagulation, oxygen, prostacyclin analogs, and endothelin-receptor blockers.

    • Main Results:

    • Parenteral prostacyclin analogs improve functional capacity and pulmonary hemodynamics.
    • The oral endothelin-receptor blocker bosentan is effective for established symptomatic PAH in SSc.
    • Calcium channel blockers are rarely effective.

    Conclusions:

    • Early screening and timely intervention are crucial for managing PAH in SSc.
    • Current therapies can improve outcomes, but challenges remain in diagnosing and treating early or presymptomatic PAH.
    • Improving early diagnosis and treatment is essential to reduce premature mortality in SSc patients.